Baker Bros. Advisors LP Kodiak Sciences Inc. Transaction History

Baker Bros. Advisors LP

  • $9.86 Billion
  • Q2 2025

A detailed history of Baker Bros. Advisors LP transactions in Kodiak Sciences Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 17,310,490 shares of KOD stock, worth $147 Million. This represents 0.65% of its overall portfolio holdings.

Number of Shares
17,310,490
Previous 17,310,490 -0.0%
Holding current value
$147 Million
Previous $48.6 Million 32.74%
% of portfolio
0.65%
Previous 0.58%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 15, 2022
BUY
$5.04 - $9.48 $6.95 Million - $13.1 Million
1,379,445 Added 8.66%
17,310,490 $132 Million
Q1 2022

May 16, 2022
BUY
$7.09 - $89.45 $8.86 Million - $112 Million
1,249,741 Added 8.51%
15,931,045 $123 Million
Q3 2021

Nov 15, 2021
BUY
$81.97 - $106.94 $44.5 Million - $58.1 Million
543,423 Added 3.84%
14,681,304 $1.41 Billion
Q2 2021

Aug 16, 2021
BUY
$77.2 - $126.54 $19.9 Million - $32.6 Million
257,929 Added 1.86%
14,137,881 $1.31 Billion
Q4 2020

Feb 16, 2021
BUY
$60.78 - $154.03 $92.9 Million - $235 Million
1,527,777 Added 12.37%
13,879,952 $2.04 Billion
Q3 2020

Nov 16, 2020
BUY
$45.05 - $59.27 $35 Million - $46.1 Million
777,637 Added 6.72%
12,352,175 $731 Million
Q1 2020

May 15, 2020
BUY
$38.18 - $73.95 $20.1 Million - $39 Million
527,249 Added 4.77%
11,574,538 $552 Million
Q4 2019

Feb 14, 2020
BUY
$13.9 - $76.65 $26.4 Million - $146 Million
1,902,173 Added 20.8%
11,047,289 $795 Million
Q3 2019

Nov 14, 2019
BUY
$10.24 - $17.57 $10 - $17
1 Added 0.0%
9,145,116 $132 Million
Q4 2018

Feb 13, 2019
BUY
$6.11 - $10.43 $55.9 Million - $95.4 Million
9,145,115 New
9,145,115 $64.9 Million

Others Institutions Holding KOD

# of Institutions
101
Shares Held
41M
Call Options Held
73.7K
Put Options Held
0
View Full List

About Kodiak Sciences Inc.

KOD Quotes by TradingView
  • Ticker KOD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,040,200
  • Market Cap $443M
  • Description
  • Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...
More about KOD
Track This Portfolio

Track Baker Bros. Advisors LP Portfolio

Follow Baker Bros. Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baker Bros. Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Baker Bros. Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email